Acquired Resistance to Osimertinib in T790M-Positive NSCLC

Video

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Geoffrey R. Oxnard, MD, assistant professor of Medicine, Dana-Farber Cancer Center, Harvard Medical School, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquiredKRAS

Recent Videos
Related Content